Table 1 Demographics, characteristics, and disease activity measures as observed on patients who entered the extension study

Age

46 (13.1)

48.7 (10)

NS

Gender (male/female)

7/1

13/5

NS

7/1

13/5

NS

7/1

13/3

NS

5/1

9/1

NS

Disease duration < 2 years, n (%)

5 (62.5)

14 (77.8)

NS

5 (62.5)

14 (77.8)

NS

5 (62.5)

12 (75)

NS

4 (66.7)

6 (60)

NS

SJC 66, median (IQR)

3.5 (3–7.3)

7 (4–8.3)

NS

0.5 (0–2)

0 (0–1)

NS

1 (0.3–2)

0 (0–1.3)

NS

0 (0–1.3)

0 (0–3.3)

NS

TJC 68, median (IQR)

5 (4–13.8)

10 (4.8–14.3)

NS

1 (0.3–3.3)

0 (0–3.3)

NS

1.5 (0.3–2.8)

1.5 (0–4.5)

NS

0 (0–1.5)

1.5 (0–4.3)

NS

PASI score, median (IQR)

2.7 (0.5–6)

1.9 (0.8–3.8)

NS

0.8 (0.4–1.7)

0

0.001

0.5 (0.5–1.8)

0

NS

1 (0.3–1.9)

0.6 (0–1.3)

NS

PASI > 2.5, n (%)

4 (50)

8 (44.4)

NS

1 (12.5)

0

NS

0

1 (6.3)

NS

0

1 (10)

NS

Pts with enthesitis, n (%)

0

2 (11.1)

NS

1 (12.5)

1 (5.6)

NS

1 (12.5)

3 (18.9)

NS

0

1 (10)

NS

Pts with dactylitis, n (%)

4 (50)

4 (22.2)

NS

1 (12.5)

0

NS

4 (50)

1 (6.3)

NS

1 (16.7)

1 (10)

NS

ESR (mm/h), median (IQR)

15.5 (5.5–24.3)

20.5 (4.3–31.8)

NS

7 (3.5–15.8)

2 (2–18)

NS

5.5 (2–10.8)

5 (2–6.5)

NS

5 (2.5–11.5)

6 (2–12)

NS

CRP (mg/L), median (IQR)

9.5 (2.1–14)

4 (1.3–14.5)

NS

3.1 (0.9–15)

1.1 (0.4–2.9)

NS

1.8 (0.7–8)

1.5 (0.4–4)

NS

4.2 (0.9–7.4)

2 (1–5)

NS

VAS patient global (mm)

26.9 (17.8)

46.3 (24.9)

NS

23.4 (25.9)

17.7 (17.6)

NS

18.3 (20.9)

24.1 (23.8)

NS

17.4 (15.2)

19.8 (20)

NS

VAS patient pain (mm)

20 (15.8)

47.7 (26.1)

0.011

8.1 (12.7)

13.6 (17.5)

NS

9.4 (8.7)

23 (21.6)

NS

6.2 (4)

21 (27.1)

NS

VAS physician (mm)

43.1 (14.0)

45.3 (15.6)

NS

12.6 (10.2)

8.1 (9.3)

NS

8.9 (8.1)

13.8 (19.6)

NS

15.6 (12.1)

13 (17.5)

NS

BASDAI

2.4 (1.8)

4.1 (1.9)

0.047

1.5 (1.6)

1.8 (1.5)

NS

1.7 (1.5)

2 (1.7)

NS

1.8 (1.7)

1.7 (1.4)

NS